We are live on
!
Find out more
WVP
Worth Venture Partners Portfolio holdings
AUM
$31.6M
1-Year Est. Return
28.5%
This Fund
S&P 500
This Quarter
Est. Return
+6.87%
1 Year Est. Return
+28.5%
3 Year Est. Return
+102.5%
5 Year Est. Return
+128.77%
10 Year Est. Return
–
AUM
$184M
AUM Growth
-$21.4M
(-10%)
Cap. Flow
-$46.6M
Cap. Flow
% of AUM
-25.37%
Top 10 Holdings %
Top 10 Hldgs %
35.95%
Holding
217
New
29
Increased
61
Reduced
33
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$5.09M |
| 2 |
GSI Technology
GSIT
|
+$2.17M |
| 3 |
Annovis Bio
ANVS
|
+$1.48M |
| 4 |
Clene
CLNN
|
+$1.45M |
| 5 |
Karyopharm Therapeutics
KPTI
|
+$1.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adtran
ADTN
|
+$4.21M |
| 2 |
Silicom
SILC
|
+$2.81M |
| 3 |
MRNS
Marinus Pharmaceuticals, Inc
MRNS
|
+$2.59M |
| 4 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$2.17M |
| 5 |
Carvana
CVNA
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.84% |
| 2 | Healthcare | 16.62% |
| 3 | Financials | 6.45% |
| 4 | Real Estate | 2.82% |
| 5 | Consumer Staples | 1.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Microchip Technology
MCHP
$42.8B
| $6.41M | 3.49% |
71,571
+64,501
| +912% | +$5.09M |
|
|
SCPH
2
DELISTED
scPharmaceuticals
SCPH
| $5.22M | 2.84% |
512,337
+1,689
| +0.3% | +$17.6K |
|
3
indie Semiconductor
INDI
$733M
| $4.83M | 2.63% |
513,835
-94,332
| -16% | -$852K |
|
4
ANI Pharmaceuticals
ANIP
$1.77B
| $4.71M | 2.56% |
87,472
+1,914
| +2% | +$84.8K |
|
5
Aviat Networks
AVNW
$262M
| $4.36M | 2.37% |
130,576
-4,680
| -3% | -$149K |
|
6
TELA Bio
TELA
$30.9M
| $4.19M | 2.28% |
413,241
+3,592
| +0.9% | +$36.7K |
|
|
TGAN
7
DELISTED
Transphorm, Inc. Common Stock
TGAN
| $3.75M | 2.04% |
1,101,680
+216,878
| +25% | +$782K |
|
|
8
GSI Technology
GSIT
$216M
| $2.76M | 1.5% |
+499,400
| New | +$2.17M |
|
9
OneMain Financial
OMF
$6.9B
| $2.12M | 1.15% |
48,433
| – | – |
|
10
Apollo Global Management
APO
$70.7B
| $2.11M | 1.15% |
27,503
| – | – |
|
11
Progressive
PGR
$124B
| $2.02M | 1.1% |
15,247
+265
| +2% | +$35.5K |
|
12
Everspin Technologies
MRAM
$354M
| $1.97M | 1.07% |
214,212
+4,850
| +2% | +$36.5K |
|
13
Franklin Covey
FC
$233M
| $1.94M | 1.05% |
44,323
-10,851
| -20% | -$402K |
|
14
Capital One
COF
$124B
| $1.93M | 1.05% |
17,661
+918
| +5% | +$91.9K |
|
15
Hilton Grand Vacations
HGV
$3.84B
| $1.8M | 0.98% |
39,541
-8,364
| -17% | -$373K |
|
16
Apyx Medical
APYX
$165M
| $1.56M | 0.85% |
309,462
+179,691
| +138% | +$910K |
|
17
Biodesix
BDSX
$228M
| $1.55M | 0.85% |
63,175
-4,835
| -7% | -$145K |
|
|
18
Annovis Bio
ANVS
$70.6M
| $1.5M | 0.81% |
+104,651
| New | +$1.48M |
|
19
BK Technologies
BKTI
$292M
| $1.36M | 0.74% |
81,951
-1,251
| -2% | -$17.6K |
|
20
Raymond James Financial
RJF
$32.5B
| $1.35M | 0.74% |
13,035
-1,685
| -11% | -$156K |
|
|
21
Clene
CLNN
$68.9M
| $1.3M | 0.71% |
+74,130
| New | +$1.45M |
|
22
GSK
GSK
$103B
| $1.18M | 0.64% |
33,200
-5,100
| -13% | -$183K |
|
23
Bank of America
BAC
$435B
| $1.16M | 0.63% |
40,273
+9,386
| +30% | +$268K |
|
24
Markel Group
MKL
$25B
| $1.15M | 0.63% |
835
+254
| +44% | +$341K |
|
25
Lightpath Technologies
LPTH
$680M
| $1.14M | 0.62% |
845,962
+9,000
| +1% | +$12.5K |
|
Similar funds
VL
WTG
QCA
SP
OGC
PE
RL
AIIC
Worth Venture Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Worth Venture Partners held 217 positions worth $184M, down 10% from $205M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Worth Venture Partners withdrew a net $46.6M in Q2 2023, closing 50 positions and reducing 33 holdings. Its most notable exit was Adtran, an estimated $4.21M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 19% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Worth Venture Partners opened a new position in GSI Technology worth $2.76M.
- Worth Venture Partners's largest Q2 2023 buy was GSI Technology: 499,400 shares worth $2.76M.
- Worth Venture Partners added most to Microchip Technology in Q2 2023, an estimated $5.09M increase.
- Worth Venture Partners's biggest Q2 2023 reduction was Marinus Pharmaceuticals, Inc, cutting an estimated $2.59M.
- Worth Venture Partners fully exited Adtran in Q2 2023, selling an estimated $4.21M.
- Worth Venture Partners's ten largest holdings make up 36% of its $184M portfolio in Q2 2023.
- Worth Venture Partners opened 29 new positions and closed 50 in Q2 2023.
- Worth Venture Partners's portfolio value fell 10% quarter-over-quarter to $184M.
Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.